Quantité totale PI	118
Rang # Quantité totale PI	11 066
Note d'activité PI	2,9/5.0    117
Rang # Activité PI	5 875
Symbole boursier	PRLD (nasdaq)
ISIN	US74065P1012
Capitalisation	52.50M  (USD)
Classe Nice dominante	Services scientifiques, technolo...

Brevets Marques 47 2 17 2 48 2 0
Dernier brevet	2025 - Brm targeting compounds and asso...
Premier brevet	2017 - Selective inhibitors of protein ...
Dernière marque	2019 - PRELUDE THERAPEUTICS
Première marque	2019 - PRELUDE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services 2024 Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds o... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to com... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to comp... Invention Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein a... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Form... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Formu... 2023 Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunction... Invention Treatment of cancers using combinations of smarca2 degraders and kras targeting therapies. Method... Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds of... Invention Kat6 targeting compounds. The present disclosure provides bifunctional compounds comprising a ta... Invention Kat6 targeting compounds with ubiquitin ligase binding moiety Invention Kat6 targeting compounds with ubiquitin ligase binding moiety. The present disclosure provides bi... Invention Processes for making prmt5 inhibitors Invention Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compou... Invention Brm targeting compounds and associated methods of use Invention 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 pr... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK ... Invention Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals. The disclosure is directed t... 2022 Invention Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prm... Invention Crystalline forms of a cdk9 inhibitor and uses thereof. The present disclosure provides novel cr... Invention Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof. Th... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK i... Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunctio... Invention Polymorphic compounds and uses thereof. The present invention provides freebase and salt forms us... 2021 Invention Heterocycle cdk inhibitors and their use thereof. The disclosure is directed to, in part, to het... Invention Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The disc... Invention Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The ... 2020 Invention Selective inhibitors of protein arginine methyltransferase 5 (prmt5). The disclosure is directed... 2019 P/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and... P/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, an...